Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Orbactiv

- PMLiVE

TMC preps filings for inclisiran after final phase 3 trials hit the mark

Less frequent dosing schedules could prove an advantage over rivals

- PMLiVE

Astellas’ Xospata scores positive CHMP recommendation

Could become a potential option for hard-to-treat leukaemia

- PMLiVE

TMC’s full data for inclisiran impresses at ESC

Marketing applications expected before end of year

- PMLiVE

TMC rockets on data for twice-yearly cholesterol drug inclisiran

Shares up 14% following announcement

- PMLiVE

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

GW Pharma’s Epidyolex also on the recommended list

- PMLiVE

ViiV bags EU okay for new two-drug HIV therapy

Rivals Gilead's Biktarvy

- PMLiVE

CHMP blocks UCB/Amgen’s Evenity approval for osteoporosis

Another obstacle for drug

- PMLiVE

Brexit “having impact on EU drug development”

EMA and UK regulator both affected

- PMLiVE

CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

Opioid dependence therapy and Pfizer's PARP inhibitor also recommended

- PMLiVE

Lilly to withdraw Lartruvo, a first for accelerated approval failures

Existing patients can use access programme

- PMLiVE

AVEO warns EU approval of Fotivda could be at risk

Concerns arose with overall survival data

- PMLiVE

CHMP recommends new Keytruda dosing schedule

Will apply to eight indications across five tumour types

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links